We found that the expression of CXCL17 was higher in clinical LUAD samples and LUAD cell lines than in lung squamous cell carcinoma (LUSC) samples and cell lines.
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report.
Five key genes (BUB1, BIRC5, CCNB2, KIF15 and SPAG5) related to mRNAsi were screened, which may act as therapeutic targets for inhibiting the stem cell characteristics of LSCC.
Five key genes (BUB1, BIRC5, CCNB2, KIF15 and SPAG5) related to mRNAsi were screened, which may act as therapeutic targets for inhibiting the stem cell characteristics of LSCC.
A lncRNA-miRNA-mRNA ceRNA network including 121 DElncRNAs, 18 DEmiRNAs and 3 DEmRNAs was established, and univariate and multivariate Cox regression analysis of those 121 DElncRNAs showed a group of 3 DElncRNAs (<i>TTTY16</i>, <i>POU6F2-AS2</i> and <i>CACNA2D3-AS1</i>) had significantly prognostic value in OS of LUSC patients.
Moreover, we found that the prognostic function of the eight miRNAs (miR-375, miR-148a, miR-29b-1 and miR-584 for LUAD; miR-4746, miR-326, miR-93 and miR-671 for LUSC).
Moreover, we found that the prognostic function of the eight miRNAs (miR-375, miR-148a, miR-29b-1 and miR-584 for LUAD; miR-4746, miR-326, miR-93 and miR-671 for LUSC).
After strict filtration, we identified three potential DMGs (POU domain, class 4, transcription factor 2 [<i>POU4F2</i>], <i>EN1</i>, single-minded homolog 1 [<i>SIM1</i>]) for early diagnosis and seven potential DEGs (G-protein coupled receptor 78 [<i>GPR78</i>], <i>PCDHA5</i>, myosin binding protein H [<i>MYBPH</i>], <i>RTL3</i>, <i>KIAA0408</i>, <i>HSD3B2</i>, <i>PCDHA12</i>) for prognosis of LUSC.
After strict filtration, we identified three potential DMGs (POU domain, class 4, transcription factor 2 [<i>POU4F2</i>], <i>EN1</i>, single-minded homolog 1 [<i>SIM1</i>]) for early diagnosis and seven potential DEGs (G-protein coupled receptor 78 [<i>GPR78</i>], <i>PCDHA5</i>, myosin binding protein H [<i>MYBPH</i>], <i>RTL3</i>, <i>KIAA0408</i>, <i>HSD3B2</i>, <i>PCDHA12</i>) for prognosis of LUSC.
After strict filtration, we identified three potential DMGs (POU domain, class 4, transcription factor 2 [<i>POU4F2</i>], <i>EN1</i>, single-minded homolog 1 [<i>SIM1</i>]) for early diagnosis and seven potential DEGs (G-protein coupled receptor 78 [<i>GPR78</i>], <i>PCDHA5</i>, myosin binding protein H [<i>MYBPH</i>], <i>RTL3</i>, <i>KIAA0408</i>, <i>HSD3B2</i>, <i>PCDHA12</i>) for prognosis of LUSC.
After strict filtration, we identified three potential DMGs (POU domain, class 4, transcription factor 2 [<i>POU4F2</i>], <i>EN1</i>, single-minded homolog 1 [<i>SIM1</i>]) for early diagnosis and seven potential DEGs (G-protein coupled receptor 78 [<i>GPR78</i>], <i>PCDHA5</i>, myosin binding protein H [<i>MYBPH</i>], <i>RTL3</i>, <i>KIAA0408</i>, <i>HSD3B2</i>, <i>PCDHA12</i>) for prognosis of LUSC.
To analyze the distribution of epidermal growth factor receptor (<i>EGFR</i>) mutations; characterize the clinical and imageological features of lung squamous cell carcinoma (LSCC) in a large population of patients; and assess correlations between clinical and imageological characteristics and clinical outcomes of LSCC patients harboring <i>EGFR</i> mutations.
Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma.
However, the clinicopathologic significance and molecular events regulated by ETV4 in lung cancer are still poorly understood, especially in squamous cell carcinoma of the lung.
In addition, DR5 expression was significantly increased in lung ADC (P<0.001), whereas, c‑FLIP was higher in lung SCC (P<0.001) and smoker patients with clinical stage III (P=0.019, P=0.016, respectively).
The Cox model analysis also indicated that the distant metastasis (<i>P</i>=0.043) could be used as an independent prognostic factor for lung adenocarcinoma patients, and the lymph node metastasis (<i>P</i>=0.045) and IFIT2 low expression (<i>P</i>=0.020) could be used as independent prognostic factors for lung squamous cell carcinoma patients.
In this study, we first identified through The Cancer Genome Atlas data analyzed that a novel synaptotagmin, SYT13, was closely related to the prognosis of lung adenocarcinoma, but was not significantly correlated with the prognosis of lung squamous cell carcinoma.